In 2012, we will continue to focus on execution as we work to invest in our future success. Our goals for this year are to continue the growth and leadership of our marketed products and the advancement of our strong pipeline. We will continue to work on risk stratification to unlock the value of TYSABRI (natalizumab) and support the continued revenue growth of AVONEX (interferon beta-1a) through the launch of the AVONEX PEN and dose titration regimen. At the same time, we will prepare to potentially launch multiple new products in the coming years, including our oral MS candidate BG‐12, as well as our long-lasting factor VIII and factor IX product candidates in hemophilia and dexpramipexole in ALS. We will also work to strengthen our early-stage pipeline through internal research and strategic collaborations to build a foundation for growth and innovation over the long term.
By focusing our resources on the areas where we have the most expertise and most promising assets, we have the greatest potential to deliver meaningful benefits for patients.